Amniotic tissue allografts can be used as a barrier in numerous clinical applications, including wound and burn care, dermatology, ophthalmology and oral surgery
Vivex Biologics, a leading regenerative medicine company specialising in the development of naturally sourced treatments, announced the launch of CYGNUS Matrix Disks, the latest configuration from the CYGNUS family of amniotic tissue allografts.
CYGNUS amniotic tissue allografts are applied as a soft tissue barrier and wound covering to help provide mechanical protection. CYGNUS Matrix Disks are a flexible, multi-layer allograft maintaining the amnion layer, its intermediate/spongy layer and the chorion layers of the amniotic sac, providing improved handling and increased workability.
“The innovative technologies associated with CYGNUS are transforming the treatment of wound care today,” said Gail Farnan, VP and GM, VIVEX’s Wound Care & Amnion Therapies business unit. “Most wounds are not square. Our modern disk design offers a size and shape that reduces the need for cutting to fit the size of the wound, enhancing the ease of use and eliminating product waste.”
Amniotic membrane is a semi-transparent and resilient membrane that lines the upper cavity of the placenta. Amniotic tissue acts as an immune-privileged protective barrier during fetal development. CYGNUS is applied as a soft tissue barrier and wound covering that helps provide mechanical protection and retains endogenous growth factors.
